OEM News, People

TriSalus Has Several Leadership Changes

The promotions of James Young, Dr. Richard Marshak, and Jodi Devlin became effective on January 6.

TriSalus Life Sciences has announced four updates to its executive leadership team. The promotions of James Young, Dr. Richard Marshak, and Jodi Devlin became effective on January 6.

TriSalus is an oncology company dedicated to improving outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies and its investigational immunotherapy. The company’s platform features FDA-cleared devices and a clinical-stage investigational immunotherapeutic, all designed to enhance treatment efficacy.

James (Jim) Young

Young, who was previously the company’s senior VP of investor relations and treasurer, was promoted to chief financial officer (CFO). He succeeds Sean Murphy, who will become the company’s chief manufacturing, strategy, and business development officer.

Before joining the company in 2023, Young was president of J Young Consulting, where he also served as interim CFO. He also provided finance organization optimization services for small- to medium-sized companies, primarily in the life sciences industry.

Before that, Young was in various finance roles of growing responsibility during a 33-year tenure at Abbott Laboratories. His most recent role there was VP and chief ethics and compliance officer.

Dr. Richard Marshak

Dr. Marshak was promoted to chief operating officer (COO) from his previous role as senior VP, corporate development, strategy and marketing. He began the role at TriSalus in June 2022.

He was previously CEO of Mount Tam Biotechnologies and co-founder of Nephragis Therapeutics. Dr. Marshak had previous positions at Abbott as well, culminating as head of global strategic pricing, which included Abbott’s flagship Humira product.

Jodi Devlin

Devlin was promoted to chief of clinical strategy and operations from her role as president, commercial operations. She joined the company for this role in August 2023.

Previously, Devlin was CEO of AltaThera Pharmaceuticals. She also touts a 21-year career at Abbott Laboratories, where she had leadership roles in pipeline planning, global launches, and management of numerous commercial organizations. She currently serves as chairman of the board at Fitabeo Therapeutics, as well.

Sean Murphy

Murphy was CFO of TriSalus since June 2022 and has been a board director since April 2020, where he served as the Chairman of the Audit Committee from August 2020 through June 2022.

Before TriSalus, Murphy was executive VP at Malin PLC, a publicly listed company that invests in life sciences companies. He was also a founding member of the Evercore HealthCare practice, and independent investment banking advisory firm.

Murphy also had a 30-year career at Abbott, with his final role as VP of business development and licensing. He serves on multiple boards of directors, including Xenex and Prenosis.

“These leadership changes reflect the momentum we’ve built and position TriSalus to achieve our ambitious goals in 2025 and beyond,” said Mary Szela, president and CEO of TriSalus. “Jim, Sean, Richard, and Jodi have each played pivotal roles in our growth and success to this point. Additionally, Jim has worked closely with Sean over the past 18 months, engaging in meticulous planning and hands-on collaboration to prepare for this transition. Together, they ensured a seamless handoff of responsibilities, equipping Jim with deep insight into the company’s financial operations and strategic objectives. This careful preparation reflects the company’s commitment to strong leadership continuity and operational excellence. I am excited to work with Richard, Jodi, Sean and Jim in their new capacities as we continue to drive innovation and patient impact. I also want to extend my sincere gratitude to Sean for his exemplary service as CFO and his continued leadership in Business Development, Manufacturing and Strategy, as well as his continued guidance as a valued board member.”

Last month, the company joined forces with Geo-Med LLC to expand availability of the TriNav Infusion System (TriNav) to U.S. Department of Veterans Affairs (VA) medical centers nationwide.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters